Assessment and Management of Diabetic Ketoacidosis

Initial Assessment

The American Diabetes Association recommends diagnostic criteria for DKA: blood glucose >250 mg/dL, arterial pH <7.3, serum bicarbonate <15 mEq/L, and presence of ketonemia or ketonuria 1
Laboratory evaluation should include plasma glucose, blood urea nitrogen/creatinine, serum ketones, electrolytes (with calculated anion gap), osmolality, urinalysis, urine ketones, arterial blood gases, complete blood count with differential, and electrocardiogram 1, 2
Obtain bacterial cultures (urine, blood, throat) if infection is suspected and administer appropriate antibiotics 1
Identify potential precipitating factors: infection, cerebrovascular accident, alcohol abuse, pancreatitis, myocardial infarction, trauma, drugs, or insulin discontinuation/inadequacy 3

Treatment Protocol

Fluid Therapy

The American College of Clinical Endocrinologists recommends beginning with isotonic saline (0.9% NaCl) at 15-20 mL/kg/hour (approximately 1-1.5 L in the average adult) during the first hour 1, 4
Subsequent fluid choice depends on hydration status, serum electrolyte levels, and urine output 1
When serum glucose reaches 250 mg/dL, change fluid to 5% dextrose with 0.45-0.75% NaCl to prevent hypoglycemia while continuing insulin therapy 4
Total fluid replacement should aim to correct estimated deficits within 24 hours 5

Insulin Therapy

Start with continuous intravenous regular insulin infusion at 0.1 units/kg/hour (preferred method for moderate to severe DKA) 2, 4
If plasma glucose does not fall by 50 mg/dL from initial value in the first hour, check hydration status; if acceptable, double the insulin infusion rate every hour until a steady glucose decline of 50-75 mg/h is achieved 5
Continue insulin infusion until resolution of ketoacidosis (pH >7.3, serum bicarbonate ≥18 mEq/L, and anion gap ≤12 mEq/L) regardless of glucose levels 4, 5

Electrolyte Management

Include 20-30 mEq/L potassium (2/3 KCl and 1/3 KPO₄) in the infusion once renal function is assured 2
Monitor potassium levels closely, as insulin administration can cause hypokalemia; maintain serum K⁺ between 4-5 mmol/L 4, 2
Bicarbonate administration is generally not recommended for DKA patients with pH >7.0 5

Monitoring During Treatment

Draw blood every 2-4 hours to determine serum electrolytes, glucose, blood urea nitrogen, creatinine, osmolality, and venous pH 4, 2
Follow venous pH (typically 0.03 units lower than arterial pH) and anion gap to monitor resolution of acidosis 4
Direct measurement of β-hydroxybutyrate in blood is the preferred method for monitoring DKA, as the nitroprusside method only measures acetoacetic acid and acetone 4, 5

Resolution Parameters

DKA resolution requires: glucose <200 mg/dL, serum bicarbonate ≥18 mEq/L, venous pH >7.3, and anion gap ≤12 mEq/L 4
Target glucose between 150-200 mg/dL until DKA resolution parameters are met 4

Transition to Subcutaneous Insulin

Once DKA is resolved, if the patient is NPO (nothing by mouth), continue intravenous insulin and fluid replacement, and supplement with subcutaneous regular insulin as needed 4
When the patient is able to eat, start a multiple-dose schedule using a combination of short/rapid-acting and intermediate/long-acting insulin 4, 2

Common Pitfalls to Avoid

Premature termination of insulin therapy before complete resolution of ketosis can lead to recurrence of DKA 5
Interruption of insulin infusion when glucose levels fall is a common cause of persistent or worsening ketoacidosis 4
Failure to add dextrose when glucose falls below 250 mg/dL while continuing insulin therapy 4
Inadequate monitoring and replacement of electrolytes, particularly potassium 4, 2
Overzealous treatment with insulin without glucose supplementation can lead to hypoglycemia 4

Management of Diabetic Ketoacidosis

Diagnostic Criteria and Treatment

The American Diabetes Association recommends that bicarbonate administration is NOT recommended for DKA patients with pH >6.9-7.0, as studies show no difference in resolution of acidosis or time to discharge with bicarbonate use 6

Transition to Subcutaneous Insulin

Once DKA is resolved, administer basal insulin (intermediate or long-acting) 2-4 hours BEFORE stopping IV insulin infusion to prevent recurrence of ketoacidosis and rebound hyperglycemia, as recommended by the American Diabetes Association 6

Management of Diabetic Ketoacidosis (DKA)

Initial Management

For critically ill and mentally obtunded patients with DKA, continuous intravenous insulin at 0.1 units/kg/hour is the standard of care, according to the American Diabetes Association 7

Insulin Therapy

Subcutaneous rapid-acting insulin analogs are equally effective and safer than IV insulin when combined with aggressive fluid management for mild-to-moderate uncomplicated DKA, as recommended by the American Diabetes Association 8, 9

Electrolyte Management

Bicarbonate is generally NOT recommended for DKA patients with pH >6.9-7.0, as stated by the American Diabetes Association, since studies show no difference in resolution of acidosis or time to discharge with bicarbonate use, and it may worsen ketosis, hypokalemia, and increase cerebral edema risk 7, 8, 9

Special Considerations

SGLT2 inhibitors must be discontinued 3-4 days before any planned surgery to prevent euglycemic DKA, as advised by the American Diabetes Association 7
Identifying and treating the underlying precipitating cause, such as infection, myocardial infarction, or insulin omission, is crucial for successful treatment of DKA, according to the American Diabetes Association 8, 9

Management of Diabetic Ketoacidosis (DKA)

Diagnostic Criteria and Treatment

The American Diabetes Association recommends that insulin therapy should not be started if significant hypokalemia is present (K+ <3.3 mEq/L), and potassium should be corrected first to avoid cardiac arrhythmias 10
Despite presenting with hypokalemia, total body potassium depletion is universal in DKA, and insulin therapy will further lower serum potassium, so potassium replacement is critical 10
If K+ <3.3 mEq/L, delay insulin therapy and aggressively replace potassium until levels reach ≥3.3 mEq/L to prevent life-threatening arrhythmias and respiratory muscle weakness 10
Target serum potassium of 4-5 mEq/L throughout treatment 10
DKA is resolved when glucose <200 mg/dL, serum bicarbonate ≥18 mEq/L, venous pH >7.3, and anion gap ≤12 mEq/L 10

Potassium Replacement and Monitoring

If K+ 3.3-5.5 mEq/L, add 20-30 mEq potassium per liter of IV fluid (use 2/3 KCl and 1/3 KPO₄) once adequate urine output is confirmed 10
If K+ >5.5 mEq/L, withhold potassium initially but monitor closely, as levels will drop rapidly with insulin therapy 10

Prevention of Complications

Inadequate potassium monitoring and replacement can lead to hypokalemia, which is a leading cause of mortality in DKA 10
Overly rapid correction of osmolality increases the risk of cerebral edema, particularly in children 10

Management of Diabetic Ketoacidosis

Initial Treatment

The American Diabetes Association recommends aggressive initial fluid replacement to restore tissue perfusion and improve insulin sensitivity, with studies showing its critical importance 11, 12
The use of bicarbonate is not recommended for pH >6.9-7.0, as studies show no benefit in resolution time or outcomes, and may worsen ketosis, cause hypokalemia, and increase cerebral edema risk 11, 12

Insulin Therapy

The American Diabetes Association suggests administering basal insulin 2-4 hours before stopping IV insulin to prevent recurrence of ketoacidosis and rebound hyperglycemia, with an overlap period essential to prevent premature termination of IV insulin 11, 12

Treatment of Underlying Cause

Identifying and treating precipitating factors, such as infection, is crucial in managing DKA, with the American Diabetes Association recommending concurrent treatment 11

Special Considerations

For mild-to-moderate uncomplicated DKA, subcutaneous rapid-acting insulin analogs combined with aggressive fluid management may be equally effective and potentially safer than IV insulin, and more cost-effective, according to the American Diabetes Association 11, 12
Continuous IV insulin remains the standard of care for critically ill and mentally obtunded DKA patients, as recommended by the American Diabetes Association 11, 12

Management of Diabetic Ketoacidosis (DKA)

Introduction to DKA Management

The American Diabetes Association recommends that for uncomplicated mild DKA, subcutaneous rapid-acting insulin analogs combined with aggressive fluid management may be equally effective, safer, and more cost-effective than IV insulin 13
The American Diabetes Association suggests that bicarbonate is generally NOT recommended for DKA patients with pH >6.9-7.0, as studies show no difference in resolution of acidosis or time to discharge 13

Non-Medical Management

The American Diabetes Association recommends identifying and treating underlying causes, such as sepsis, myocardial infarction, stroke, or discontinuing precipitating medications, including SGLT2 inhibitors which must be discontinued 3-4 days before any planned surgery to prevent euglycemic DKA 13, 14
The American Diabetes Association suggests that patient education before discharge should include identification of outpatient diabetes care providers, understanding of diabetes diagnosis, glucose monitoring, home glucose goals, and when to call healthcare professional 13

Transition to Subcutaneous Insulin

The American Diabetes Association recommends administering basal insulin 2-4 hours before stopping IV insulin infusion to prevent recurrence of ketoacidosis and rebound hyperglycemia 13

Management of Diabetic Ketoacidosis

Identification and Treatment

The American Diabetes Association, as reported in Diabetes Care, recommends considering other triggers for DKA, such as myocardial infarction, stroke, pancreatitis, trauma, insulin omission, or SGLT2 inhibitor use, and obtaining bacterial cultures if infection is suspected 15
For mild-moderate uncomplicated DKA, subcutaneous rapid-acting insulin analogs combined with aggressive fluid management may be equally effective, safer, and more cost-effective than IV insulin, according to the American Diabetes Association, as reported in Diabetes Care 15
The American Diabetes Association, as reported in Diabetes Care, suggests administering basal insulin 2-4 hours before stopping IV insulin infusion to prevent recurrence of ketoacidosis and rebound hyperglycemia 15
Adding low-dose basal insulin analog during IV insulin infusion can help prevent rebound hyperglycemia, as recommended by the American Diabetes Association, as reported in Diabetes Care 15

Diabetic Ketoacidosis Treatment Guidelines

Introduction to DKA Management

The American Diabetes Association recommends that for mild-to-moderate uncomplicated DKA, subcutaneous rapid-acting insulin analogs combined with aggressive fluid management are equally effective, safer, and more cost-effective than IV insulin, requiring adequate fluid replacement, frequent point-of-care glucose monitoring, and treatment of concurrent infections 16
The American Diabetes Association suggests treating underlying precipitating causes concurrently, such as administering appropriate antibiotics if infection is suspected, and managing myocardial infarction or stroke 16

Insulin Therapy and Management

The American Diabetes Association recommends starting multiple-dose schedule using a combination of short/rapid-acting and intermediate/long-acting insulin once DKA is resolved and the patient can eat, with basal insulin administered 2-4 hours before stopping IV insulin infusion 16
The American Diabetes Association suggests continuing IV insulin and fluid replacement, supplementing with subcutaneous regular insulin as needed, if the patient remains NPO after DKA resolution 16

Bicarbonate Administration and Acidosis Management

The American Diabetes Association notes that studies show no difference in resolution of acidosis or time to discharge with bicarbonate use, and bicarbonate may worsen ketosis, cause hypokalemia, and increase cerebral edema risk 16

Treatment of Severe Ketoacidosis

Initial Fluid Resuscitation

The American Diabetes Association recommends beginning with isotonic saline (0.9% NaCl) at 15-20 mL/kg/hour to restore intravascular volume and renal perfusion, and when glucose falls to 200-250 mg/dL, switch to 5% dextrose with 0.45-0.75% saline while continuing insulin infusion to prevent hypoglycemia and ensure complete ketoacidosis resolution 17

Critical Electrolyte Management

The American Diabetes Association suggests that bicarbonate is NOT recommended for pH >6.9-7.0, as multiple studies show no difference in resolution of acidosis or time to discharge, and bicarbonate may worsen ketosis, cause hypokalemia, and increase cerebral edema risk 17, 18

Treatment of Underlying Precipitating Factors

The American Diabetes Association recommends identifying and treating correctable causes such as sepsis, myocardial infarction, stroke, pancreatitis, or infection 17, 18

Alternative Approach for Mild-Moderate Uncomplicated DKA

The American Diabetes Association suggests that subcutaneous rapid-acting insulin analogs combined with aggressive fluid management are equally effective, safer, and more cost-effective than IV insulin for uncomplicated mild-moderate DKA, and continuous IV insulin remains standard for critically ill and mentally obtunded patients 17, 18

Transition to Subcutaneous Insulin

The American Diabetes Association recommends administering basal insulin (intermediate or long-acting) 2-4 hours BEFORE stopping IV insulin to prevent recurrence of ketoacidosis and rebound hyperglycemia, and recent evidence shows adding low-dose basal insulin analog during IV insulin infusion may prevent rebound hyperglycemia without increasing hypoglycemia risk 17

Management of Diabetic Ketoacidosis with Potassium Considerations

Critical Potassium Management

Total body potassium depletion in DKA averages 3-5 mEq/kg body weight, and insulin therapy will unmask this depletion by driving potassium intracellularly, requiring massive potassium repletion during treatment 19
The American Diabetes Association guidelines recommend confirming adequate urine output before aggressive potassium repletion, and if anuric or oliguric, potassium repletion must be more cautious with nephrology consultation 19

Ongoing Potassium Monitoring

Despite total body potassium depletion being universal in DKA, only a small percentage of patients present with hypokalemia, making this a high-risk scenario, and potassium levels should be checked every 2-4 hours during active treatment, although no specific citation is provided for this fact, the previous fact about total body potassium depletion is relevant 19

Management of Diabetic Ketoacidosis

Introduction to DKA Management

The American Diabetes Association recommends that bicarbonate is not administered for pH >6.9-7.0, as studies show no benefit in resolution time or outcomes and may worsen ketosis, cause hypokalemia, and increase cerebral edema risk 20

Insulin Therapy

The American Diabetes Association suggests administering basal insulin 2-4 hours before stopping IV insulin infusion to prevent recurrence of ketoacidosis and rebound hyperglycemia 20
Adding low-dose basal insulin analog during IV insulin infusion may prevent rebound hyperglycemia without increasing hypoglycemia risk 20

Special Considerations

The American Diabetes Association notes that cerebral edema occurs more commonly in children and adolescents than adults and is one of the most dire complications of DKA, and monitoring closely for signs of altered mental status, headache, or neurological deterioration is crucial 20

Discharge Planning

The American Diabetes Association recommends identifying outpatient diabetes care providers before discharge, educating patients and families on glucose monitoring, insulin administration, and recognition and treatment of hyperglycemia/hypoglycemia, and scheduling follow-up appointments prior to discharge 20

Management of Diabetic Ketoacidosis

Initial Diagnostic Workup and Treatment

The American Diabetes Association recommends continuous intravenous regular insulin as the standard of care for moderate-to-severe DKA or critically ill/mentally obtunded patients, with a target glucose decline of 50-75 mg/dL per hour 21

Insulin Therapy Protocol

For hemodynamically stable, alert patients with mild-to-moderate DKA, subcutaneous rapid-acting insulin analogs combined with aggressive fluid management are equally effective, safer, and more cost-effective than IV insulin, according to the American Diabetes Association 21

Bicarbonate Administration

The American Diabetes Association does not recommend bicarbonate for DKA patients with pH >6.9-7.0, as multiple studies show no difference in resolution of acidosis or time to discharge with bicarbonate use, and it may worsen ketosis, cause hypokalemia, and increase cerebral edema risk 21

Special Considerations and Pitfalls

The American Diabetes Association recommends discontinuing SGLT2 inhibitors immediately and not restarting until infection is resolved and patient is metabolically stable, and advises against restarting SGLT2 inhibitors until 3-4 days after any acute illness to prevent DKA 21

Transition to Subcutaneous Insulin

The American Diabetes Association recommends administering basal insulin (glargine or detemir) 2-4 hours before stopping the IV insulin infusion to prevent recurrence of ketoacidosis and rebound hyperglycemia 21

Management of Diabetic Ketoacidosis in the ICU

Initial Assessment and Diagnosis

For critically ill and mentally obtunded patients with DKA in the ICU, continuous intravenous regular insulin at 0.1 units/kg/hour is the standard of care, as recommended by the American Diabetes Association 22

Special Considerations for Mild-Moderate Uncomplicated DKA

For hemodynamically stable, alert patients with mild-moderate uncomplicated DKA, subcutaneous rapid-acting insulin analogs combined with aggressive fluid management are equally effective, safer, and more cost-effective than IV insulin, according to the American Diabetes Association 22
This approach requires adequate fluid replacement, frequent point-of-care glucose monitoring, treatment of concurrent infections, and appropriate follow-up, as suggested by the American Diabetes Association 22

Transition to Subcutaneous Insulin

Administer basal insulin (intermediate or long-acting) 2-4 hours BEFORE stopping IV insulin infusion to prevent recurrence of ketoacidosis and rebound hyperglycemia, as recommended by the American Diabetes Association 22

Common Pitfalls in ICU Management

Stopping IV insulin without prior administration of basal subcutaneous insulin causes rebound hyperglycemia and ketoacidosis, as noted by the American Diabetes Association 22

Management of Diabetic Ketoacidosis (DKA)

Insulin Therapy

The American Diabetes Association recommends continuous intravenous regular insulin at 0.1 units/kg/hour as the standard of care for moderate-to-severe DKA or critically ill patients, according to the Diabetes Care guideline 23
For mild-to-moderate uncomplicated DKA, subcutaneous rapid-acting insulin analogs combined with aggressive fluid management are equally effective, safer, and more cost-effective than IV insulin for hemodynamically stable, alert patients, as stated in the Diabetes Care guideline 23

Bicarbonate Administration

The American Diabetes Association suggests that bicarbonate is NOT recommended for DKA patients with pH >6.9-7.0, as multiple studies show no difference in resolution of acidosis or time to discharge, and it may worsen ketosis, cause hypokalemia, and increase cerebral edema risk, according to the Diabetes Care guideline 23

Transition to Subcutaneous Insulin

The American Diabetes Association recommends administering basal insulin 2-4 hours BEFORE stopping IV insulin infusion to prevent recurrence of ketoacidosis and rebound hyperglycemia, as stated in the Diabetes Care guideline 23

Diabetic Ketoacidosis Management

Initial Treatment and Assessment

The American Diabetes Association recommends initial therapy for youth with new-onset diabetes and ketoacidosis should address hyperglycemia and metabolic derangements regardless of ultimate diabetes type, with adjustment once metabolic compensation established 24

Insulin Therapy

The standard IV insulin protocol for moderate-severe DKA involves an initial bolus of 0.1 units/kg IV regular insulin, followed by a continuous infusion of 0.1 units/kg/hour regular insulin, with a target glucose decline of 50-75 mg/dL per hour 24

Transition to Subcutaneous Insulin

Administer basal insulin (glargine or detemir) 2-4 hours before stopping IV insulin infusion to prevent recurrence of ketoacidosis and rebound hyperglycemia, as recommended by the American Association of Clinical Endocrinologists 24

Management of Diabetic Ketoacidosis (DKA)

Introduction to DKA Management

The American Diabetes Association recommends that for hemodynamically stable, alert patients with mild-moderate DKA, subcutaneous rapid-acting insulin analogs at 0.15 units/kg every 2-3 hours combined with aggressive fluid management are equally effective, safer, and more cost-effective than IV insulin 25
Bicarbonate is NOT recommended for DKA patients with pH >6.9-7.0, as multiple studies show no difference in resolution of acidosis or time to discharge, and it may worsen ketosis, cause hypokalemia, and increase cerebral edema risk 25

Special Considerations

The American Diabetes Association suggests discontinuing SGLT2 inhibitors immediately and not restarting until 3-4 days after metabolic stability is achieved, as these medications can precipitate euglycemic DKA 25

Discharge Planning

The American Diabetes Association recommends educating patients on recognition, prevention, and management of DKA to prevent recurrence and readmission 25
Ensure appropriate insulin regimen is prescribed with attention to medication access and affordability, as recommended by the American Diabetes Association 25

Diabetic Ketoacidosis Management

Precipitating Factors

Glucocorticoid use can precipitate hyperglycemia and DKA in patients with diabetes, according to the American Diabetes Association 26
Myocardial infarction can both precipitate and be masked by DKA, and should be considered in the differential diagnosis, as recommended by the American Heart Association 26
Cerebrovascular accident (stroke) can precipitate DKA, and patients should be assessed for focal neurological deficits during physical examination, as suggested by the American Stroke Association 26

Management

Treatment of the underlying cause of DKA must occur simultaneously with correction of the metabolic derangement, as recommended by the American Diabetes Association 26

Diabetic Ketoacidosis Management

Insulin Therapy

The American Diabetes Association recommends administering basal insulin 2-4 hours before stopping IV insulin infusion to prevent recurrence of ketoacidosis and rebound hyperglycemia, with a target glucose between 150-200 mg/dL until DKA resolution parameters are met 27
Recent evidence shows that adding low-dose basal insulin analog during IV insulin infusion may prevent rebound hyperglycemia without increasing hypoglycemia risk, according to the American Association of Clinical Endocrinologists 27

Transition to Subcutaneous Insulin

The American College of Endocrinology suggests starting multiple-dose schedule using combination of short/rapid-acting and intermediate/long-acting insulin once the patient can eat, with an initial dose of approximately 0.5-1.0 units/kg/day for newly diagnosed patients 27

Euglycemic Diabetic Ketoacidosis: Definition, Risk Factors, Diagnosis, and Management

Definition & Diagnostic Criteria

Euglycemic DKA is defined by blood glucose < 200–250 mg/dL together with arterial pH < 7.3, serum bicarbonate < 15–18 mEq/L, anion gap > 12 mEq/L, and ketonemia or ketonuria (ADA) 28.

Risk Factors & Precipitants

SGLT2‑Inhibitor Use

SGLT2 inhibitors are the leading contemporary cause of euglycemic DKA; they should be stopped immediately when DKA is suspected (ADA) 28.
These agents lower the renal glucose threshold, which can mask the hyperglycemia that normally alerts clinicians to DKA (ADA) 29.
Incidence: 0.6–4.9 events per 1,000 patient‑years in type 2 diabetes, with a relative risk of 2.46 versus placebo (ADA) 28.

Pregnancy

≈ 2 % of pregnancies in women with pre‑gestational diabetes develop DKA, frequently presenting with euglycemia (glucose < 200 mg/dL) (ADA) 28.

Acute Illness with Reduced Oral Intake

Concurrent illness causing nausea/vomiting and decreased oral intake can precipitate euglycemic DKA (ADA) 28.

Diagnostic Approach

Laboratory Evaluation

β‑hydroxybutyrate (β‑OHB) measurement in blood is the preferred diagnostic test because nitroprusside‑based assays miss the predominant ketone body (ADA) 29.
Blood glucose will be < 200–250 mg/dL by definition (ADA) 28.

Pitfalls

Nitroprusside‑based urine or blood ketone tests detect only acetoacetate and acetone, missing β‑OHB; they should not be used for diagnosis or monitoring (ADA) 29.
During successful treatment, acetoacetate may rise as β‑OHB falls, potentially giving a false impression of worsening ketosis if nitroprusside methods are employed (ADA) 29.

Management & Monitoring

Monitoring of Ketosis

Serial β‑hydroxybutyrate levels should be measured (when available) to track resolution of ketosis (ADA) 29.
Reduction in blood β‑OHB is the most accurate marker of successful treatment (ADA) 29.

Prevention & Patient Education

For Patients on SGLT2 Inhibitors

Discontinue SGLT2 inhibitors immediately during any acute illness and do not restart until 3–4 days after metabolic stability is achieved (ADA) 28.
Check urine or blood ketones during illness even if glucose is normal (ADA) 28.
Avoid prolonged fasting, very‑low‑carbohydrate diets, and excessive alcohol intake while taking SGLT2 inhibitors (ADA) 28.

General DKA Prevention

Never stop basal insulin, even when oral intake is limited; provide detailed sick‑day management instructions (ADA) 28.
Measure ketones when glucose exceeds 200 mg/dL or during any illness with typical DKA symptoms (ADA) 28.
Seek immediate medical attention if the patient cannot tolerate oral hydration, develops altered mental status, or symptoms worsen despite home management (ADA) 28.

Special Populations

Pregnancy

Pregnant individuals may present with euglycemic DKA and mixed acid‑base disturbances, especially in the setting of hyperemesis (ADA) 28.
Because of the high risk of fetal‑maternal harm, pregnant patients at risk should be counseled on DKA signs and instructed to seek prompt medical care (ADA) 28.

Type 2 Diabetes

DKA can occur in type 2 diabetes, particularly when SGLT2 inhibitors are used (ADA) [29][28].
Autoimmune markers increase the risk of euglycemic DKA in type 2 diabetes patients on SGLT2 inhibitors (ADA) 28.

Acute Management of Severe Hyperglycemia

Initial Fluid Resuscitation

Begin aggressive isotonic saline (0.9 % NaCl) at 15–20 mL kg⁻¹ hour⁻¹ (≈1–1.5 L in the first hour) for all patients with severe hyperglycemia requiring ICU‑level care. 30, 31

Diagnostic Evaluation

Obtain stat laboratory studies including plasma glucose, arterial or venous pH, serum electrolytes with anion gap, β‑hydroxybutyrate (preferred ketone test), BUN and creatinine, calculated effective serum osmolality (2 × [Na] + glucose/18), urinalysis with ketones, complete blood count, ECG, and bacterial cultures if infection is suspected. 30, 31

Diagnostic Criteria

Diabetic ketoacidosis (DKA) is defined by glucose > 250 mg/dL, arterial pH < 7.3, serum bicarbonate < 15 mEq/L, moderate‑to‑large ketonuria/ketonemia, and anion gap > 12 mEq/L. 30, 31
Hyperosmolar hyperglycemic state (HHS) is defined by glucose > 600 mg/dL, arterial pH > 7.3, serum bicarbonate > 15 mEq/L, minimal ketonuria/ketonemia, effective serum osmolality ≥ 320 mOsm/kg, and altered mental status or severe dehydration. 31
Mixed DKA/HHS presentations (features of both disorders) can occur in the same patient. 31

Fluid Management After the First Hour

Calculate corrected serum sodium (add 1.6 mEq/L for each 100 mg/dL glucose above 100 mg/dL).
- If corrected sodium is normal or elevated, switch to 0.45 % NaCl at 4–14 mL kg⁻¹ hour⁻¹. 30
- If corrected sodium is low, continue 0.9 % NaCl at 4–14 mL kg⁻¹ hour⁻¹. 30
When glucose falls to ≈ 250 mg/dL (DKA) or ≈ 300 mg/dL (HHS), change IV fluids to 5 % dextrose with 0.45–0.75 % NaCl while maintaining insulin infusion. 31

Potassium Management

Total body potassium depletion is universal (≈3–5 mEq/kg in DKA, 4–6 mEq/kg in HHS). 30
If serum K⁺ < 3.3 mEq/L: hold insulin and replace potassium aggressively until K⁺ ≥ 3.3 mEq/L. 30
If K⁺ = 3.3–5.5 mEq/L: add 20–30 mEq potassium per liter of IV fluid (≈2/3 KCl, 1/3 KPO₄) once adequate urine output is confirmed. 30
If K⁺ > 5.5 mEq/L: withhold potassium initially, monitor every 2–4 hours as levels will fall with insulin therapy. 30
Target serum potassium throughout treatment: 4–5 mEq/L. 30

Insulin Therapy

Confirm serum potassium ≥ 3.3 mEq/L before initiating insulin.
Give an IV bolus of regular insulin 0.1–0.15 U kg⁻¹, then start a continuous infusion of 0.1 U kg⁻¹ hour⁻¹. 31
Aim for a glucose decline of 50–75 mg/dL per hour. If the decline is < 50 mg/dL in the first hour and hydration is adequate, double the infusion rate each hour until a steady decline is achieved. 31
Continue insulin infusion until DKA resolution (pH > 7.3, bicarbonate ≥ 18 mEq/L, anion gap ≤ 12 mEq/L) regardless of glucose level; when glucose reaches ≈ 250 mg/dL, add dextrose to the IV fluids while maintaining insulin. 31

Monitoring During Treatment

Draw blood every 2–4 hours for serum electrolytes, glucose, BUN, creatinine, osmolality, and venous pH (arterial gases generally unnecessary). 31
Use β‑hydroxybutyrate measurements for monitoring ketosis resolution; avoid nitroprusside‑based ketone tests, which miss the predominant ketone body. 31

Identification and Treatment of Precipitating Causes

Common precipitants that should be sought and treated concurrently include infection, myocardial infarction, cerebrovascular accident, insulin omission or inadequacy, pancreatitis, SGLT2‑inhibitor use, glucocorticoid therapy, and pregnancy. 30, 31
Obtain bacterial cultures and start appropriate antibiotics when infection is suspected. 30

Cited Common Pitfalls

Starting insulin before correcting hypokalemia (K⁺ < 3.3 mEq/L) can cause life‑threatening arrhythmias. 31
Stopping insulin when glucose falls to ≈ 250 mg/dL (instead of adding dextrose and continuing insulin) leads to recurrent ketoacidosis. 31
Using nitroprusside‑based ketone tests for monitoring misses β‑hydroxybutyrate and may delay appropriate therapy. 31